Meeting
2014 ASCO Annual Meeting
A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial).
Authors
Ursula Matulonis
Dana-Farber Cancer Institute, Boston, MA
Ursula Matulonis , Sven Mahner , Robert Michael Wenham , Jonathan A. Ledermann , Bradley J. Monk , Jose Maria Del Campo , Jonathan S. Berek , Ignace Vergote , Michel Fabbro , Dionyssios Katsaros , Christian Marth , Domenica Lorusso , Jorn Herrstedt , Shefali Agarwal , Robert E. Martell , Mansoor Raza Mirza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01847274
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS5625)
DOI
10.1200/jco.2014.32.15_suppl.tps5625
Abstract #
TPS5625
Poster Bd #
400A
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).
First Author: Ursula A. Matulonis
Poster
2021 ASCO Annual Meeting
Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial.
First Author: Jing Wang
Poster
2017 ASCO Annual Meeting
Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy.
First Author: Mansoor Raza Mirza
Poster
2017 ASCO Annual Meeting
The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).
First Author: Jose Maria Del Campo